Pharmacotherapy of Child and Adolescent Psychiatric Disorders -- List of Contributors -- Foreword -- Chapter 1 Historical Perspectives on Child and Adolescent Psychopharmacology -- References -- Chapter 2 Pharmacoepidemiology of Psychotropic Medications in Youth -- Introduction -- Prevalence and trends for medications prescribed for ADHD -- Nonstimulant medications for ADHD -- Antidepressant medication -- Antipsychotic medication -- Alpha-agonists -- Anticonvulsant "mood stabilizers" -- Concomitant psychotropic medication -- Preschool psychotropic medication use -- International patterns of psychotropic medication for youth -- Conclusion -- References -- Chapter 3 Off-Label Prescribing of Drugs in Child and Adolescent Psychiatry -- Introduction -- Extent of off-label prescribing -- Need for psychoactive drug treatments for children and adolescents -- Legislation supporting pediatric drug development -- Recommendations to follow when considering off-label prescribing -- References -- Chapter 4 The Use of Generic Drugs in Pediatric Psychopharmacology -- What is a generic drug? -- Why are we discussing generic drugs? -- Basic requirements for generic drugs -- The status of regulations regarding generic drugs and children -- Abbreviated new drug application (ANDA) requirements -- Pediatric assessments of adult drugs (history up to current status) -- Best Pharmaceuticals for Children Act -- Pediatric Research Equity Act -- Intersection of requirements for generics and pediatric assessment -- Future directions -- Concluding thoughts -- References -- Chapter 5 Psychoactive Drug Use in Children: Basic Concepts in Clinical Pharmacology -- Introduction -- Basic concepts in pharmacokinetics -- Dosing considerations for psychoactive drugs in children -- Summary -- References -- Chapter 6 Psychostimulants -- Introduction -- Epidemiology of stimulant use.

Structure and biochemical mechanism of action -- Neuroimaging studies of stimulant effects -- Studies of short-term efficacy -- Studies of long-term efficacy -- Clinical use -- Common side-effects -- Cardiovascular safety issues -- Growth suppression -- Substance use and diversion -- Comparison with nonstimulant treatment -- Treatment of comorbidity -- Pharmacogenetics -- Conclusions -- References -- Chapter 7 Tricyclic Antidepressants and Monoamine Oxidase Inhibitors for the Treatment of Child and Adolescent Psychiatric Disorders -- Tricyclic antidepressants (TCAs) -- Drug interactions, contraindications -- Monoamine oxidase inhibitors (MAOIs) -- General summary -- References -- Chapter 8 Selective Serotonin Reuptake Inhibitors (SSRIs) -- Pharmacokinetics -- Initiation and titration -- Indications and efficacy -- Adverse effects -- Withdrawal -- References -- Chapter 9 Novel (Atypical) Antidepressants -- Novel (atypical) antidepressants -- General overview -- Bupropion -- Duloxetine -- Mirtazapine -- Trazodone -- Venlafaxine -- Desvenlafaxine -- Alternative treatments -- Summary -- References -- Chapter 10 Antipsychotic Agents -- Introduction -- Chemical properties -- Typical antipsychotics -- Atypical antipsychotics -- Ethical issues: treatment of at-risk populations -- Conclusions -- References -- Chapter 11 Lithium -- Introduction -- Pharmacology -- Potential mechanisms of action -- Evidence for the use of lithium in children and adolescents -- Dosing and drug monitoring -- Contraindications, precautions, and drug interactions -- Side-effects -- References -- Chapter 12 Anticonvulsants Used in Child and Adolescent Psychiatric Disorders -- Introduction -- Divalproex sodium -- Carbamazepine -- Oxcarbazepine -- Lamotrigine -- Gabapentin -- Topiramate -- Conclusion -- References -- Chapter 13 Anxiolytics -- Chemical properties -- Indications.

Contraindications -- Adverse effects -- Overdose -- Abuse/dependence -- Drug interactions -- Available preparations and cost -- Initiation and maintenance of treatment -- Management of specific side-effects -- How to withdraw medication -- References -- Chapter 14 Adrenergic Agents in Child and Adolescent Psychiatry -- Clonidine and guanfacine -- Guanfacine -- Beta-blockers -- Acknowledgements -- References -- Chapter 15 Atypical Psychopharmacologic Strategies -- Opiate antagonists -- Memantine -- Riluzole -- Secretin -- Topiramate -- Herbal medications and dietary supplements -- Ginkgo (Ginkgo biloba) -- Melatonin -- Omega-3 fatty acids -- St. John's wort (Hypericum perforatum) -- Valerian (Valeriana officinalis) -- Conclusion -- References -- Chapter 16 Psychopharmacology in Preschool Children -- Introduction -- Developmental considerations -- Rise in psychopharmacology use -- Psychotherapy before psychopharmacology -- When psychopharmacology may be considered as a first line: pragmatic considerations -- Psychopharmacology in preschool disorders: administration and monitoring -- Off-label prescribing: special considerations -- Use of psychotropics in specific disorders -- Summary -- References -- Chapter 17 Combination Pharmacotherapy for Psychiatric Disorders in Children and Adolescents -- Bipolar disorder -- Major depressive disorder -- Attention-deficit hyperactivity disorder -- Obsessive-compulsive disorder -- Tics and Tourette's syndrome -- Pervasive developmental disorders -- Conclusion -- References -- Index.